Share information
274.00 €
-0.36 %
13/04/2026 17:35
-0.36 %
Open
High
Low
Volume
270.00 €
278.40 €
270.00 €
247,174
Latest News
10-Apr-2026
Acquisition of own shares
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa